The IVISbrite™ BxPC3 Red F-luc tumor cell line (Bioware® Brite BxPC3-Red-FLuc) is a light-producing cell line derived from BxPC3 human pancreatic adenocarcinoma. The cells have been stably transduced with the red-shifted firefly luciferase gene from Luciola Italica (Red F-luc), for a brighter, red-shifted signal.
For research use only. Not for use in diagnostic procedures.
false false
IVISbrite BxPC3 Red F-luc Bioluminescent Tumor Cell line
This cell line has very bright bioluminescence, emitting at least 15,000 photons/cell/sec in vitro. The exact number will vary depending on imaging and culturing conditions.
By emitting intensified, longer wavelength light that is significantly brighter than other firefly luciferases, our bioluminescent oncology cell lines allow you to visualize and monitor the growth of deep tissue tumors in vivo.
After the cells are injected into an appropriate mouse model, the optimized Red F-luc luciferase enables more sensitive in vivo optical detection with less tissue attenuation so you can detect tumor development earlier, and monitor tumor growth and metastases in both subcutaneous and orthotopic models.
| 腫瘤細胞係 | Pancreatic |
|---|---|
| 熒光素酶分類 | Firefly |
| 產品品牌名稱 | IVISbrite |
| 包裝量 | 2.0 Vials |
| 運輸條件 | 幹冰 |
| 產品尺寸 | 2 million cells |
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
Our comprehensive range of bioluminescent and fluorescent imaging reagents provide researchers with the necessary tools to better understand early disease-related biological changes, track disease progression, help guide the drug discovery process, and evaluate efficacy and safety of drug candida ...
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...
